← Back to headlines
Novo Nordisk Shares Plunge After Obesity Drug Fails to Outperform Zepbound
Novo Nordisk's shares experienced a significant drop after its obesity drug did not demonstrate superior efficacy compared to Zepbound in clinical trials.
23 Feb, 16:44 — 23 Feb, 16:44
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Daily wage increase for minimum wage earners in Davao Region
just now
Bureau of Customs Auctions More Discaya Luxury Vehicles for P25.7 Million
just now
New Offer to Warner Bros. Questions Netflix's $83 Billion Deal
3m ago
Moskauer Ökonomin: „Chinesen können langfristig denken. Aber im Kreml haben wir keine Chinesen“ [premium]
5m ago